Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended) A composition of matter ~~capable of producing an anti-inflammatory response~~ *in vivo* ~~in a mammal, said composition~~ comprising bodies selected from the group consisting of liposomes, solid beads, hollow beads and filled beads, ~~capable of being phagocytosed in vivo by mammalian antigen-presenting cells resulting in the alteration of the cytokine profile of cells of the mammalian immune system,~~ further wherein the bodies have ~~having~~ a size from about 20 nanometers to 500 microns in diametric dimension, still further wherein the bodies contain or are capable of expressing or expressible on the surface thereof an active group ~~containing~~ comprising the peptide sequence RGD,~~-~~ wherein the bodies are capable of being phagocytosed *in vivo* in a mammal by mammalian antigen-presenting cells resulting in the alteration of the cytokine profile of cells of the mammalian immune system and thereby producing an anti-inflammatory response *in vivo* in said mammal.

Claim 2 (currently amended) The composition ~~Composition~~ of matter according to claim 1, wherein the bodies contain on their surface thereof an active group comprising the peptide sequence RGD ~~comprising a three-dimensional body portions selected from liposomes, solid beads, hollow beads and filled beads~~.

Claim 3 (original)   The composition ~~Composition~~ of matter according to claim 2 wherein the active ~~peptide~~ group is the peptide sequence RGDS.

Claims 4 – 12 (canceled)

Claim 13 (currently amended)   A ~~process~~ method of alleviating or inhibiting the symptoms of inflammation in a mammalian patient, which comprises administering to the patient an effective amount of a composition of matter comprising synthetic bodies having a three-

025.4221.1

dimensional core structure of size from 20 nanometers to 500 microns expressing or expressible on the surface thereof RGDS ligands which will react, optionally in the presence of adapter molecules, with at least one specific receptor wherein the binding of said ligand with said receptors produces an anti-inflammatory response *in vivo* in said mammal.

Claim 14 (new)   The method according to claim 13, wherein the symptoms of inflammation are caused by a neurodegenerative disorder.

Claim 15 (new)   The method according to claim 14, wherein the neurodegenerative disorder is Parkinson's disease.

Claim 16 (new)   The method according to claim 14, wherein the neurodegenerative disorder is Alzheimer's disease.

Claim 17 (new)   The method according to claim 13, wherein the symptoms of inflammation are caused by a cardiovascular disease.

Claim 18 (new)   The method according to claim 17, wherein the cardiovascular disease is atherosclerosis.

Claim 19 (new)   The method according to claim 13, wherein the symptoms of inflammation are caused by an autoimmune disease.

Claim 20 (new)   The method according to claim 13, wherein the symptoms of inflammation are caused by endothelial dysfunction.